Introduction:
Last Updated 20 May 2010 As one of the most severe infections within the spectrum of
respiratory tract infections, community-acquired pneumonia (CAP) is an
important and potentially lucrative area for antibacterial drug development.
While the majority of CAP patients are treated in the outpatient setting, the
inpatient setting—where treatment costs can be as much as 20-50 times higher than
in the outpatient setting—represents more than half of the CAP market and is
the area of highest commercial growth over the next ten years. Despite being a
highly competitive and mature market, CAP is characterized by untapped market
opportunities for new therapies that are active against key drug-resistant
pathogens and that can demonstrate efficacy in the moderate to severe CAP
population.
Questions Answered in This Report:
*
Several key antibiotics for the treatment of CAP will
experience patent expiry during our 2008-2018 forecast period, specifically
levofloxacin (Johnson & Johnson’s Levaquin, Sanofi-Aventis’s Tavanic, and
Daiichi Sankyo’s Cravit), moxifloxacin (Bayer/Merck/Shionogi’s Avelox),
linezolid (Pfizer’s Zyvox), and piperacillin/tazobactam (Pfizer’s Zosyn).
What
will be the impact of these brands’ generic erosion on the overall CAP market?
Which emerging therapies, if any, will find commercial success despite
increasing genericization of the CAP market?
*
Two anti-MRSA cephalosporins—Johnson & Johnson/Basilea
Pharmaceutica’s ceftobiprole and Forest Laboratories/AstraZeneca/Takeda’s
ceftaroline—are expected to enter the inpatient CAP market early in our
forecast period (2010-2011).
How will physicians incorporate these new
cephalosporins into their treatment of CAP? How effectively will these agents
compete with generic ceftriaxone and soon-to-be generic levofloxacin, the
current leaders of the inpatient CAP market?
*
The late-stage pipeline for CAP comprises at least nine drugs,
including an anti-MRSA quinolone, a second-generation oxazolidinone, an oral
carbapenem, and agents from two new drug classes (streptogramins and
aminomethylcyclines).
How will these agents fare in the highly mature and
competitive CAP market? What drug attributes will differentiate these
therapies from current and emerging therapies? What impact will the launch of
these drugs have on the growth of the CAP market?
*
MRSA is becoming an increasingly prevalent pathogen in CAP.
What
are physician perceptions regarding the need for novel MRSA therapies for the
treatment of CAP? Which emerging therapies have activity against MRSA, and what
are physicians’ opinions of these drugs, especially with respect to anti-MRSA
activity?Scope:
Markets covered: United States, France, Germany,
Italy, Spain, United Kingdom, Japan.
Primary research: 17 country-specific interviews with
specialists in infectious disease and respiratory medicine.
Epidemiology: Diagnosed and drug-treated populations,
for both the inpatient and outpatient populations.
Population segments in market forecast: Inpatient and
outpatient.
Emerging therapies: Phase II: 6 drugs; Phase III: 3
drugs; preregistration: 1 drug. Phase I: 1 product.
Market forecast features: Bottom-up, patient-based
forecast of the inpatient and outpatient antibiotic market, by drug, through
2018.